Haemline

Haemline Team
  • 0.0 (0)
  • Education

Haematology learning on-the-go, made by UK haematologists who know you're busy, tired, and possibly holding a sandwich. Whether you're commuting, tidying up, or too spent to open a book, we aim to deliver short episodes to fit into your daily grind. From blood basics to niche deep dives, there's something for students, specialists, and the haemo-curious. Most episodes are tightly scripted for a solo host, crafted to feel like a clear, helpful colleague talking it through. Designed to support evidence-based thinking habits that outlast outdated exam knowledge. New episodes most weeks.

  1. 08/04/2025

    War of the Cords: Optimising Graft-versus-Leukaemia in Double Cord Blood Transplantation

    In double cord blood transplantation, one unit engrafts and the other is rejected—but the losing unit might be doing more than previously imagined. A 2025 Blood Advances study from the Eurocord–EBMT registry reveals how the immunological battle between cord units can be redirected against leukaemia, particularly when the patient and losing unit share the right HLA mismatches. In this episode, we unpack the elegant biology behind this unintended vaccine effect, explore the surprising lack of excess GVHD, and consider what these findings mean for unit selection in high-risk disease. Could the losing graft be the key to preventing relapse? Episode Type: Deep dive intended for leukaemia and transplant health care professionals Reference: Wynn R, et al. Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation. Blood Adv. 2025 May 2:bloodadvances.2025015938. doi: 10.1182/bloodadvances.2025015938. Epub ahead of print. PMID: 40315369.

    16 min

  2. 07/26/2025

    Deep Dive: Paediatric/AYA AML Transplant Decisions in the Molecular Era

    Which children and young adults with acute myeloid leukaemia should receive transplant in first remission? This episode explores a landmark 2025 analysis from the Children's Oncology Group that revisits this longstanding question through a contemporary molecular lens. Huang and colleagues, publishing in the Journal of Clinical Oncology, analysed outcomes for over 1,400 patients from the AAML0531 and AAML1031 trials—studies that enrolled patients up to age 29. By retrospectively applying contemporary molecular risk criteria from the current AAML1831 trial, including newly recognised adverse genetic lesions and measurable residual disease thresholds, they revealed striking patterns in transplant benefit across redefined risk groups. We unpack how this molecular reclassification informs our understanding of transplant outcomes, from the substantial improvements in disease-free survival for most high-risk patients to the unexpected findings in certain subgroups like monosomy 7. Along the way, we explore what these retrospective insights might mean for clinical practice in the genomic era of AML management—from approaches to molecular profiling at diagnosis to considerations around transplant timing in first remission. Episode type: Deep Dive—intended for leukaemia and transplant health care professionals or scientists involved in AML diagnostics or research. Reference: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children’s Oncology Group by Huang BJ et al., Journal of Clinical Oncology, 2025. DOI: 10.1200/JCO-24-01841

    29 min

  3. 07/25/2025

    Rapid Review: Paediatric/AYA AML Transplant Decisions in the Molecular Era

    Which children and young adults with acute myeloid leukaemia should receive transplant in first remission? In this Rapid Review, we explore a landmark analysis by Huang et al., published in the Journal of Clinical Oncology in April 2025. Reclassifying over 1,400 patients using AAML1831 criteria, the study offers a contemporary perspective on who gains from transplant—and who doesn't. The results are compelling: disease-free survival doubles for most molecularly defined high-risk patients, while those with monosomy 7 or 5 continue to fare poorly despite transplant. This three-minute overview highlights key findings and clinical implications, including donor timing, MRD integration, and the future role of targeted agents. The over-arching message is clear—biology now defines benefit. Episode type: Rapid Review of a key paper for anyone interested in AML biology or treatment Reference: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children’s Oncology Group by Huang BJ et al., Journal of Clinical Oncology, 2025. DOI: 10.1200/JCO-24-01841

    6 min

  4. 07/20/2025

    First-Line Ven/Aza/Revumenib for AML?

    Could targeting the menin–KMT2A axis up front improve outcomes in older adults with NPM1-mutated or KMT2A-rearranged AML? In this episode, we examine new phase I data from Zeidner and colleagues, published in The Journal of Clinical Oncology in June 2025, investigating revumenib in combination with azacitidine and venetoclax for newly diagnosed patients ineligible for intensive therapy. We explore the shared biological mechanism linking these two subtypes, the rationale for adding menin inhibition to ven/aza, and early results—including high remission rates, MRD nuances, and challenges around myelosuppression and treatment delays. How do these outcomes compare to VIALE-A? Could molecular MRD clearance inform future consolidation strategies? And where might this triplet fit among the growing field of ven/aza-based combinations? Episode type: Deep Dive potentially relevant to anyone carrying for acute leukaemia patients or interested in menin inhibitors more generally.

    12 min

  5. 07/20/2025

    Targeting Menin in Acute Leukaemia: AUGMENT-101 Results

    Building on our earlier Biology Tangent episode on menin inhibition, this clinical deep-dive explores the pivotal AUGMENT-101 trial results that led to FDA approval of revumenib — the first licensed menin inhibitor for acute leukaemias. Revumenib has shown meaningful activity in relapsed or refractory KMT2A-rearranged and NPM1-mutated acute leukaemias, illustrating how targeting transcriptional dependencies can restore differentiation, even in heavily pretreated patients. We examine key efficacy data, including CR/CRh rates of 23 percent — exceeding historical expectations — with nearly 40 percent of responders proceeding to transplant. The episode also explores biomarkers of response, such as IDH co-mutations; the expected safety profile, marked by differentiation syndrome and QTc prolongation; and emerging resistance mechanisms likely to influence future therapeutic development. Episode type: Deep Dive suitable for anyone involved in caring for acute leukaemia patients, or interested in menin inhibitors generally.

    17 min

  6. 07/19/2025

    Mechanism to Medicine: Menin as Model

    How does understanding normal blood cell development lead to breakthrough cancer therapies? This Biology Tangent episode explores the science behind menin inhibitors - therapies that act across age groups, lineages, and genetic subtypes by targeting shared developmental circuitry. We examine why both KMT2A-rearranged and NPM1-mutated leukaemias depend on this unexpected vulnerability, and how disrupting a single protein can unlock differentiation across multiple cancer types. From chromatin regulation to differentiation syndrome, we trace the biological logic that makes this approach so compelling. Beyond the elegant science, it’s a story about uncovering common ground between seemingly distinct cancers with implications reaching well beyond haematology. Menin is a case study in why long-term investment in fundamental biology matters: decades spent unravelling HOX genes and chromatin complexes have enabled oral, outpatient therapy for leukaemias once considered untreatable. A story for clinicians, researchers, and anyone curious about the bridge between mechanism and medicine. Episode type: Biology Tangent

    12 min

  7. 07/17/2025

    Bonus Episode: “What analyser does your lab use and why?” (a fair FRCPath question)

    A deeper dive for haematology trainees and biomedical scientists. This bonus episode explores the technology behind specific modern full blood count analysers—including Sysmex, Beckman Coulter, Abbott, Siemens, and Roche—and why analyser choice matters clinically, diagnostically, and even in exams. Episode type: Core Haematology

    17 min

  8. 07/14/2025

    Reticulocytes, CHr, and IRF: The Most Useful Tests You’re Not Using?

    The 2am anaemia admission. The four-year-old who’s "a bit tired" with a normal Hb and MCV. The anaemic dialysis patient with a mildly raised ferritin. In each case, reticulocyte parameters could change your clinical decision-making. Join us to explore how modern analysers reveal not just red cell quantity but quality, why CHr outperforms ferritin in detecting early iron deficiency, and how IRF predicts marrow recovery before counts improve. Depending on where you work, all of these tests may already be at your fingertips. It’s time to start using them.

    15 min
See All (14)

About

Haematology learning on-the-go, made by UK haematologists who know you're busy, tired, and possibly holding a sandwich. Whether you're commuting, tidying up, or too spent to open a book, we aim to deliver short episodes to fit into your daily grind. From blood basics to niche deep dives, there's something for students, specialists, and the haemo-curious. Most episodes are tightly scripted for a solo host, crafted to feel like a clear, helpful colleague talking it through. Designed to support evidence-based thinking habits that outlast outdated exam knowledge. New episodes most weeks.

Information

  • Creator
    Haemline Team
  • Years Active
    2K
  • Episodes
    14
  • Rating
    Clean
  • Copyright
    © 2025 Haemline
  • Show Website
    Haemline